Market Cap: $24B
IC
Incyte Corporation
INCY
NASDAQ (NASDAQ Global Select)USD
Market Cap: $24B
Incyte Corporation (Ticker: INCY) is currently making strides in the oncology and rare disease sectors with groundbreaking developments in their therapeutic pipeline. The company recently reported piv…
Incyte Corporation (Ticker: INCY) makes significant strides in the oncology and rare disease sectors, showcasing critical advancements that hold promise for patients and investors alike. Through recen…
Incyte Corporation (Ticker: INCY) has recently made a significant move within the healthcare sector through its acquisition of Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1…
Incyte Corporation (Ticker: INCY) is currently gaining attention for its successful Phase 3 frontMIND trial results, which investigated the efficacy of tafasitamab and lenalidomide in combination with…
Incyte Faces Divergent Analyst Opinions Amid Evolving Biopharmaceutical Landscape Incyte Corporation stands at a crossroads, with a recent evaluation from 13 analysts revealing a spectrum of opinions…
Incyte: A Study in Contrasting Analyst Perspectives Amidst a Dynamic Biopharmaceutical Landscape Incyte Corporation stands at a pivotal junction within the biopharmaceutical landscape, as recent evalu…
### Olumiant's Promising Path for Treating Adolescent Alopecia Areata Eli Lilly and Company is making significant strides in the treatment landscape for severe alopecia areata (AA) in adolescents, fol…
Eli Lilly Advances Alopecia Areata Treatment for Adolescents with Olumiant Eli Lilly and Company announces a pivotal step forward in the treatment of severe alopecia areata (AA) among adolescents, fol…
Semiconductor process intensity tightens supply and services demand Semiconductor suppliers report rising intensity in etch, deposition and materials services as chipmakers increase process complexity…
Chip‑making materials and services tighten as AI demand lifts fab intensity Semiconductor materials and wafer‑processing service providers report stronger orders and firmer near‑term outlooks as custo…
AI-driven demand expands cloud security and observability footprints Enterprise customers increasingly bundle cloud security, observability and analytics as AI projects scale, a trend showing up in re…
Macro data next week tightens funding and credit plans for yte U.S. jobs and inflation releases, delayed briefly by the government and now scheduled together next week, put the Federal Reserve outlook…
Interest-data double release pushes yte to reshape fixed-income posture Interest-rate sensitive asset manager yte is recalibrating its fixed-income positioning as U.S. jobs and inflation reports, dela…
Incyte Advances Hematological Treatment with Tafasitamab in DLBCL Incyte Corporation's recent announcement regarding the Phase 3 frontMIND trial marks a significant milestone in the treatment landscap…
Incyte's Promising Advances in DLBCL Treatment: tafasitamab Shows Potential in Phase 3 Trial Incyte Corporation's recent announcement concerning the pivotal Phase 3 frontMIND trial demonstrates a sign…
Incyte Corporation Advances Treatment for Myeloproliferative Neoplasms with INCA033989 Incyte Corporation presents promising clinical data from two Phase 1 studies of INCA033989, an investigational dr…
Incyte Advances Treatment Options for Myeloproliferative Neoplasms with INCA033989 Incyte Corporation (NASDAQ: INCY) recently unveils promising clinical data from two Phase 1 studies of its investigat…
Emerging Stability in a Volatile Market: The Shift from Tech to Resilient Sectors In recent days, the stock market landscape reveals a significant shift as investors reassess their strategies amidst t…
Incyte Corp Faces Increased Short Interest Amid Market Scrutiny Incyte Corp, a biopharmaceutical company focused on discovering and developing innovative medicines, experiences a significant rise in s…
Incyte Corp Faces Rising Short Interest Amid Market Scrutiny Incyte Corp, a biopharmaceutical company known for its focus on oncology and other serious diseases, is currently experiencing a significan…
Technological Resilience: Nasdaq’s Gains Reflect Sector Strength Recent market activity underscores the resilience and vitality of the technology sector, as evidenced by the Nasdaq Composite's signifi…
Incyte Corporation Reports Robust Q3 Revenue, Showcasing Strong Market Position Incyte Corporation, a prominent player in the biotechnology sector, announces its third-quarter financial results, highl…
Ebglyss: A New Hope for Atopic Dermatitis Patients Eli Lilly and Co. recently reveals promising results from clinical trials for its innovative treatment, Ebglyss (lebrikizumab-lbkz), aimed at patient…
Incyte Analysts Provide Mixed Insights Amid Biopharmaceutical Developments Incyte Corporation (NASDAQ: INCY) stands at a crossroads within the biopharmaceutical sector as analysts weigh its potential…
Uncovering Growth Opportunities in the S&P 500 In a recent episode of "Mad Money," Jim Cramer emphasizes the potential for investors to discover undervalued stocks within the S&P 500, even as market i…
Incyte Corporation: Navigating the Complexities of the Biotechnology Landscape Incyte Corporation, a leading player in the biotechnology sector, faces a multifaceted landscape as it works to advance i…
Incyte Corporation: Navigating Analyst Perspectives in a Competitive Biotech Landscape Incyte Corporation (INCY) currently stands at a crossroads, as 13 analysts weigh in on the company's future withi…
Incyte's Promising Myelofibrosis Therapy Fuels Investor Optimism In a notable development within the biopharmaceutical sector, Incyte Corporation garners attention this week as its stock surges follow…
Incyte Corporation: Navigating a Complex Biopharmaceutical Landscape Incyte Corporation is currently at a pivotal point within the biopharmaceutical sector, as recent assessments from 12 analysts reve…
Incyte Corporation: Navigating a Complex Biopharmaceutical Landscape Incyte Corporation (INCY) faces a dynamic environment in the biopharmaceutical sector, as recent assessments from 12 analysts yield…
Biogen's Focus on Neurology: Strengthening its Competitive Edge Biogen stands at a pivotal moment as it prepares to unveil its quarterly earnings on July 31, 2025. The biotechnology company is recogni…
Incyte Corporation's Strong Q2 Performance Highlights Innovation and Growth Incyte Corporation (INCY) demonstrates robust performance in its second-quarter financial results, achieving a revenue of $1…
Incyte’s Strategic Leadership Signals Confidence in Biopharmaceutical Growth Incyte Corporation, a notable player in the biopharmaceutical industry, continues to reinforce its commitment to innovative…
Emerging Leadership in Diverse Sectors Signals Robust Market Rally In a recent segment of "Mad Money," Jim Cramer highlights a significant shift in market dynamics, showcasing a diverse leadership acr…
Incyte's Breakthrough in Myeloproliferative Neoplasms Treatment with INCA033989 Incyte Corporation (INCY) is making strides in the battle against myeloproliferative neoplasms (MPNs) with its investiga…
Strategic Collaboration Enhances Oncology Treatment Access in Asia-Pacific Specialised Therapeutics (ST), an independent biopharmaceutical company, announces a significant expansion of its partnership…
Incyte Corporation: Navigating Analyst Perspectives Amid Industry Uncertainties Incyte Corporation (INCY) finds itself at the center of a diverse array of analyst opinions as industry experts evaluate…
Incyte Corporation: Navigating a Complex Future in Biopharmaceuticals Incyte Corporation finds itself at a crossroads, as recent insights from eight analysts reveal a diverse array of opinions regardi…
Abeona Therapeutics Inc. Launches Groundbreaking Gene Therapy for Rare Skin Condition Abeona Therapeutics Inc. achieves a significant milestone with the U.S. Food and Drug Administration's (FDA) appro…
Abeona Therapeutics Achieves Milestone with FDA Approval of Groundbreaking Gene Therapy Abeona Therapeutics Inc. reaches a significant milestone as the U.S. Food and Drug Administration (FDA) grants a…
Abeona Therapeutics Pioneers Gene Therapy for Rare Skin Condition Abeona Therapeutics Inc. achieves a significant milestone with the FDA's recent approval of its groundbreaking gene-modified cellular…
Klarna Takes Center Stage with Walmart Partnership, Displacing Affirm In a significant shake-up within the fintech landscape, Klarna is set to replace Affirm as Walmart's exclusive provider of buy now…
Norwegian Cruise Line's Resilience Amid Market Fluctuations Norwegian Cruise Line (NCL) stands out in the current market landscape as it experiences a notable 4% increase in its share price. This surg…
Incyte Expands Workforce with Strategic Stock Awards to Attract Talent Incyte, a prominent player in the biopharmaceutical industry, recently announces the grant of restricted stock unit awards (RSUs)…
Incyte Sets Stage for Fourth Quarter Results Announcement Incyte, a prominent player in the biopharmaceutical sector, gears up for its fourth quarter and year-end 2024 financial results conference cal…
Incyte Prepares for Year-End Financial Results Announcement, Highlighting Commitment to Therapeutics Development Incyte, a biopharmaceutical company based in Wilmington, Delaware, is set to announce i…
Incyte Strengthens Leadership with New Executive Appointment Incyte Corporation, a leading biopharmaceutical company headquartered in Wilmington, Delaware, enhances its executive team with the appoint…
Incyte's Tafasitamab Study Marks a Breakthrough in Follicular Lymphoma Treatment Incyte Corporation recently unveils promising results from the Phase III inMIND study, which evaluates Tafasitamab (Mon…
### Incyte Expands Workforce with Restricted Stock Unit Awards Incyte, a leading biopharmaceutical company based in Wilmington, Delaware, takes a significant step to enhance its talent pool by grantin…
Incyte Strengthens Workforce with Restricted Stock Grants for New Hires Incyte Corporation, a prominent biopharmaceutical company based in Wilmington, Delaware, takes significant steps to enhance its…